Want to see AU:ZNO full AI Analyst Report?
Top Page
Zoono Group Limited
(Sydney:ZNO)
Select Model
Select Model
Rating:45Neutral
Price Target:
AU$0.05
▼(-42.50% Downside)
Action:Reiterated
Date:10/29/26
The score is primarily held back by weak financial performance, driven by multi-year losses and consistent cash burn despite a 2026 revenue rebound and gross margin recovery. Technicals add modest pressure given the price remains below key moving averages with a negative MACD. Valuation is also constrained by negative earnings (negative P/E) and no dividend yield data to offset profitability risk.
Positive Factors
Revenue and Gross Margin Recovery
The rebound in revenue and gross margin shows meaningful operational improvement after the severe deterioration of 2024–2025. If maintained, stronger sales and product-level economics could improve operating leverage and provide a foundation for restoring profitability over the next several quarters.
Negative Factors
Persistent Unprofitability
Despite the sales and gross-margin rebound, Zoono has not converted improved trading activity into sustainable earnings. Five consecutive loss-making years and a deeply negative 2026 net margin indicate that operating costs or other expenses remain too high for the current revenue base.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue and Gross Margin Recovery
The rebound in revenue and gross margin shows meaningful operational improvement after the severe deterioration of 2024–2025. If maintained, stronger sales and product-level economics could improve operating leverage and provide a foundation for restoring profitability over the next several quarters.
Read all positive factors
Zoono Group Limited (ZNO) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$21.33M
Dividend Yield2.08%
Average Volume (3M)74.72K
Price to Earnings (P/E)―
Beta (1Y)0.32
Revenue Growth28.77%
EPS Growth59.60%
CountryAU
Employees2
SectorConsumer Defensive
Sector Strength42
IndustryHousehold & Personal Products
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding453,884,220
10 Day Avg. Volume177,888
30 Day Avg. Volume74,725
Financial Highlights & Ratios
PEG Ratio0.22
Price to Book (P/B)7.42
Price to Sales (P/S)14.50
P/FCF Ratio-16.22
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Zoono Group Limited Business Overview & Revenue Model
Company Description
Zoono Group Limited, along with its associated entities, specializes in the innovation, development, and global distribution of a variety of antimicrobial solutions, catering to both the New Zealand market and international clientele. Their produc...
Zoono Group Limited Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
56
Neutral
Cash Flow
22
Negative
| Breakdown | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 1.49M | 1.16M | 960.30K | 3.07M | 8.13M |
| Gross Profit | 595.90K | -281.53K | -4.36M | -625.33K | 2.10M |
| EBITDA | -1.22M | -3.11M | -8.03M | -342.66K | -4.91M |
| Net Income | -1.59M | -3.64M | -8.30M | -321.97K | -10.28M |
Balance Sheet | |||||
| Total Assets | 5.28M | 5.87M | 9.01M | 13.40M | 17.68M |
| Cash, Cash Equivalents and Short-Term Investments | 220.15K | 47.30K | 1.79M | 759.99K | 3.30M |
| Total Debt | 298.54K | 544.56K | 726.63K | 868.36K | 1.00M |
| Total Liabilities | 2.37M | 2.89M | 2.76M | 3.24M | 8.41M |
| Stockholders Equity | 2.91M | 2.97M | 6.24M | 10.16M | 10.00M |
Cash Flow | |||||
| Free Cash Flow | -1.33M | -1.58M | -2.89M | -3.55M | -996.61K |
| Operating Cash Flow | -1.33M | -1.58M | -2.89M | -3.55M | -974.11K |
| Investing Cash Flow | -349.00 | 0.00 | -58.73K | -53.49K | -107.62K |
| Financing Cash Flow | 1.50M | -190.15K | 3.99M | 873.62K | -54.99K |
Zoono Group Limited Technical Analysis
Neutral
0.08
Price Trends
0.05
Positive
0.05
Negative
0.06
Negative
Market Momentum
>-0.01
Negative
51.96
Neutral
100.94
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:ZNO, the sentiment is Neutral. The current price of 0.08 is above the 20-day moving average (MA) of 0.05, above the 50-day MA of 0.05, and above the 200-day MA of 0.06, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 51.96 is Neutral, neither overbought nor oversold. The STOCH value of 100.94 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for AU:ZNO.
Zoono Group Limited Peers Comparison
UnderperformOutperform
Sector (62)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
45 Neutral | AU$21.33M | -11.75 | -50.40% | 2.08% | 28.77% | 59.60% | |
44 Neutral | AU$4.76M | -2.11 | -49.07% | ― | -33.53% | 42.98% | |
43 Neutral | AU$18.71M | -0.89 | -33.14% | 4.92% | -14.87% | -35.60% | |
41 Neutral | AU$3.92M | -1.10 | -43.04% | 221.43% | -29.84% | 22.51% | |
41 Neutral | AU$6.97M | -0.44 | -430.23% | ― | -50.64% | -72.00% |
* Consumer Defensive Sector Average
AU:ZNO
Zoono Group Limited
0.05
<0.01
2.17%
AU:PTL
Pental Ltd.
0.02
-0.03
-52.08%
AU:MCP
Mcpherson'S Limited
0.13
-0.13
-49.02%
AU:EVE
EVE Health Group Limited
0.01
-0.02
-56.67%
AU:SKN
Skin Elements Limited
―
―
―
Zoono Group Limited Corporate Events
Zoono Group Launches Speculative Rights Issue to Raise $1.6m
Oct 22, 2026
Zoono Group Limited has launched a pro rata non-renounceable rights issue, offering eligible shareholders one new share for every ten held at an issue price of $0.039, aiming to raise about $1.61 million before costs. The offer, which the company ...
Zoono Group Plans Non-Renounceable Pro Rata Share Issue
Oct 22, 2026
Zoono Group Limited is an ASX-listed company operating in the hygiene and antimicrobial products sector. It develops and markets sanitising and protective solutions, with its shares trading under the ticker ZNO, providing access to equity capital ...
Zoono launches rights issue to bolster capital while maintaining board control
Oct 22, 2026
Zoono Group Limited, a New Zealand-headquartered biotech firm, specialises in long-lasting antimicrobial sprays, wipes and foams for skin, surfaces and mould remediation, based on its proprietary ‘ZOONO molecule’. Its products, positio...
Zoono launches rights issue and placement to fund global product development
Oct 22, 2026
Zoono Group Limited has launched a pro-rata non-renounceable rights issue, offering one new share for every ten held at $0.039 per share to raise up to A$1.61 million before costs. The proceeds are earmarked for a shelf-life extension project in k...
Zoono boosts capital with share placement and cleansing notice
Oct 22, 2026
Zoono Group Limited has issued 6,410,256 new fully paid ordinary shares at $0.039 per share via a placement to an existing shareholder, bolstering its capital base. The company has lodged a cleansing notice to ensure the new shares can be freely t...
Zoono Group Raises Fresh Capital via Single-Investor Share Placement
Oct 22, 2026
Zoono Group Limited has applied for quotation of new ordinary fully paid shares on the ASX, under its existing code ZNO. The company completed a placement to a single investor, issuing 6,410,256 shares dated October 23, 2026, as part of an additio...
Zoono Raises A$250,000 to Accelerate Food Shelf-Life Technology and Asian Expansion
Oct 22, 2026
Zoono Group Limited, a biotech firm specialising in durable antiviral and antibacterial products for consumer and industrial use, is expanding its reach in shelf-life extension technologies for global food producers and retailers. Its proprietary ...
Zoono Group Options Lapse, Trimming Potential Share Dilution
Oct 20, 2026
Zoono Group Limited has reported the cessation of a tranche of listed options in its capital structure, specifically the ZNOAP options that were scheduled to expire on June 30, 2026. These options, exercisable at $0.35, formed part of the company&...
Zoono expands global shelf-life trials and shipping-container coatings
Oct 19, 2026
Zoono Group reported continued progress in commercialising its shelf-life extension products during the quarter to 30 September 2026, highlighting broader trials with major retailers in the U.K. on strawberries and raspberries and preparing expans...
Zoono Directors Reshuffle Shareholdings to Signal Confidence
Sep 25, 2026
Zoono Group Limited has disclosed a change in directors’ interests after Non-Executive Director Marc Braterman sold 782,022 shares via an off-market trade at $0.05 per share to fund a personal matter, while retaining rights to acquire up to ...
Zoono lodges updated ASX corporate governance statement for FY26
Aug 27, 2026
Zoono Group Limited has lodged its updated corporate governance statement for the year ended 30 June 2026 and confirmed it is available on the company’s investor website. The statement, current as of 27 August 2026 and approved by the board,...
Zoono Narrows Annual Loss as Revenue Rises but Keeps Dividend on Hold
Aug 27, 2026
Zoono Group Limited reported a 37.9% increase in revenues from ordinary activities to NZ$1.72 million for the year ended 30 June 2026, while significantly narrowing its loss after tax. The loss attributable to owners fell by around half to NZ$1.84...
Zoono posts strong FY27 start on shelf-life orders and online sales
Aug 3, 2026
Zoono Group Limited has reported a strong start to its FY27 financial year, driven by continuing shelf-life extension orders that delivered unaudited July sales of about NZ$625,000 and an unaudited profit of NZ$110,000. The company also noted impr...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.